Target Non-HDL Cholesterol for Patients with Diabetes
For patients with type 2 diabetes and cardiovascular disease (CVD) or chronic kidney disease (CKD), or those >40 years with additional CVD risk factors, the target non-HDL cholesterol is <100 mg/dL (2.6 mmol/L). 1
Risk-Based Target Stratification
The non-HDL cholesterol target varies based on cardiovascular risk level in patients with diabetes:
Very High Risk Patients
- Target: <85 mg/dL (2.2 mmol/L) 2
- This applies to patients with:
- Type 2 diabetes AND established CVD
- Type 2 diabetes AND CKD
- Type 2 diabetes >40 years with ≥1 additional CVD risk factors or target organ damage
High Risk Patients
- Target: <100 mg/dL (2.6 mmol/L) 1
- This applies to patients with:
- Type 2 diabetes without additional risk factors
- Type 2 diabetes without evidence of target organ damage
Lower Risk Patients
- Target: <130 mg/dL (3.4 mmol/L) 1
- This applies to patients with type 2 diabetes and no additional risk factors
Clinical Context and Treatment Approach
The 2016 ESC/EAS guidelines provide the most definitive risk-stratified targets, establishing non-HDL-C as a secondary goal after LDL-C targets are addressed. 1 The primary goal remains LDL-C reduction (<70 mg/dL for very high risk, <100 mg/dL for high risk), with non-HDL-C serving as an important secondary target that captures all atherogenic lipoproteins.
Why Non-HDL-C Matters in Diabetes
Non-HDL cholesterol is particularly important in diabetes because:
- Patients with diabetes frequently have elevated triglycerides, which means they carry more triglyceride-rich lipoproteins not captured by LDL-C alone 3, 4
- Research shows significant discordance between LDL-C and non-HDL-C goal attainment, especially when triglycerides are elevated 5, 6
- Among diabetic patients achieving LDL-C <100 mg/dL, 10-11% still have non-HDL-C >130 mg/dL 7
Practical Treatment Algorithm
When triglycerides are ≥200 mg/dL, non-HDL-C becomes the more relevant target than LDL-C alone 8:
- First-line therapy: Statins to achieve LDL-C goal
- If non-HDL-C remains elevated: Consider adding ezetimibe 4
- For persistent elevation: Consider fibrate or niacin, though combination therapy requires careful monitoring 8
Common Pitfalls
- Don't ignore non-HDL-C when LDL-C is at goal: Up to 18% of patients meeting LDL-C targets fail to meet non-HDL-C targets 9
- Triglyceride levels strongly predict non-HDL-C goal attainment: The relationship is continuous and inverse—higher triglycerides make non-HDL-C goals progressively harder to achieve 5
- Non-HDL-C calculation is simple: Total cholesterol minus HDL-C, requiring no fasting sample 7
Updated 2023 ADA Guidance
The most recent ADA Standards 10 recommend moderate-to-high intensity statin therapy for adults with diabetes aged 40-75 years, with consideration for non-HDL-C monitoring, though they focus primarily on LDL-C targets rather than specifying absolute non-HDL-C goals. The 2017 ACC pathway 3 suggests considering non-HDL-C ≥130 mg/dL as a threshold for treatment intensification in primary prevention.
The European guidelines provide more explicit non-HDL-C targets that align with cardiovascular risk stratification, making them the most actionable for clinical practice. 1, 2